Sciences Ii L Pptv Iv, L.P.... Net Worth

The estimated Net Worth of Sciences Ii L Pptv Iv, L.P.... is at least $52.4 million dollars as of 25 July 2017. Sciences P owns over 1,090,909 units of Apollo Endosurgery Inc stock worth over $52,433,720 and over the last 7 years Sciences sold APEN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sciences P APEN stock SEC Form 4 insiders trading

Sciences has made over 1 trades of the Apollo Endosurgery Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Sciences bought 1,090,909 units of APEN stock worth $6,000,000 on 25 July 2017.

The largest trade Sciences's ever made was buying 1,090,909 units of Apollo Endosurgery Inc stock on 25 July 2017 worth over $6,000,000. On average, Sciences trades about 1,090,909 units every 0 days since 2017. As of 25 July 2017 Sciences still owns at least 5,243,372 units of Apollo Endosurgery Inc stock.

You can see the complete history of Sciences P stock trades at the bottom of the page.

Insiders trading at Apollo Endosurgery Inc

Over the last 12 years, insiders at Apollo Endosurgery Inc have traded over $3,882,241 worth of Apollo Endosurgery Inc stock and bought 10,717,094 units worth $45,588,363 . The most active insiders traders include Holdings A/S Novo, Neil Gagnon et R Kent Jr Mc Gaughy. On average, Apollo Endosurgery Inc executives and independent directors trade stock every 41 days with the average trade being worth of $2,726,880. The most recent stock trade was executed by Jeffrey G. Black on 25 February 2022, trading 40,000 units of APEN stock currently worth $229,200.

What does Apollo Endosurgery Inc do?

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Complete history of Sciences P stock trades at Apollo Endosurgery Inc

Apollo Endosurgery Inc executives and stock owners

Apollo Endosurgery Inc executives and other stock owners filed with the SEC include:

• Christopher Gostout,
  Chief Medical Officer
• Todd Newton,
  Chief Executive Officer, Director
• John J. Molesphini,
  Exec. VP of Operations
• Bret Schwartzhoff,
  Vice President - North America Sales and Global Marketing
• Stefanie Cavanaugh,
  Chief Financial Officer, Secretary
• K. Todd Newton,
  Consultant
• Bret Schwartzhoff,
  VP, US Sales & Global Marketing
• Julie Shimer,
  Independent Director
• Bruce Robertson,
  Independent Director
• David Pacitti,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• William McClellan,
  Independent Director
• John Barr,
  Independent Director
• Rick Anderson,
  Independent Director
• John Molesphini,
  Executive Vice President - Operations
• Dr. Christopher J. Gostout M.D.,
  Co-Founder & Chief Medical Officer
• Jeffrey G. Black,
  Chief Financial Officer
• Dr. Pankaj Jay Pasricha FACP, M.D., MBBS,
  Co-Founder
• Dr. Christopher J. Gostout,
  Co-Founder & Chief Medical Officer
• Sydney Chung M.D.,
  Co-Founder and Innovation Partner
• Dr. Peter Benjamin Cotton M.D.,
  Co-Founder and Innovation Partner
• Dr. Robert Hawes M.D.,
  Co-Founder and Innovation Partner
• Anthony Kalloo M.D.,
  Co-Founder and Innovation Partner
• Dr. Sergey Kantsevoy M.D.,
  Co-Founder and Innovation Partner
• Charles S. McKhann,
  CEO, Pres & Director
• Sciences Ii L Pptv Iv, L.P....,
  
• Ventures Llc Remeditex,
  10% owner
• Richard J Meelia,
  Director
• Dennis L. Mc Williams,
  President, CCO
• Ventures Endosurgery, Llc...,
  10% owner
• Holdings A/S Novo,
  10% owner
• John W Creecy,
  Director
• Charles Tribie,
  Executive V.P. of Operations
• Chas Mc Khann,
  President and CEO
• Sciences Ii L Pptv Iv, L.P....,
  
• Sciences Ii L Pptv Iv, L.P....,
  
• Capital, L.P. Stonepine,
  10% owner
• Sciences Ii L Pptv Special ...,
  
• Inc Cpmg,
  
• James W Jr Traweek,
  
• Neil Gagnon,
  10% owner
• Sciences Ii L Pptv Iv, L.P....,
  
• Inc Desai Antal Rohit Cpmg,
  
• Matthew S Crawford,
  10% owner
• Jeffrey G. Black,
  Chief Financial Officer
• Mike Gutteridge,
  VP, Int'l Sales and Marketing
• Sharon O'keefe,
  Director
• Jeannette Bankes,
  Director